GlassScriptPhysician profile
Lauren Respess
NPI 1043784648
$4,651.59
in general payments reported to CMS, 2019-2025
34 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $847 · 2023: $1,264 · 2024: $1,137 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,577.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.47 | 2021-2025 | |
| Novo Nordisk INC | $589.20 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $443.65 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Noven Therapeutics, LLC | $276.79 | 2023-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $244.42 | 2021-2025 | Trintellix |
| Amneal Pharmaceuticals LLC | $214.99 | 2023-2025 | Unithroid |
| Axsome Therapeutics, INC. | $201.21 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $185.52 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $184.85 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $183.56 | 2022-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.41 | 2022-2025 | Xifaxan, Trulance |
| Tolmar, INC. | $145.53 | 2023-2025 | Jatenzo |
| Alkermes, INC. | $138.65 | 2022-2025 | Aristada, Vivitrol, Vivitrol |
| Astellas Pharma US INC | $97.81 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $90.17 | 2023-2025 | Accrufer |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $85.75 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.25 | 2022-2023 | Glyxambi, Jardiance, Synjardy |
| Pfizer INC. | $82.53 | 2022-2025 | |
| Amgen INC. | $57.57 | 2021-2024 | Repatha |
| Boston Scientific Corporation | $44.98 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $40.15 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $37.39 | 2022 | |
| Dexcom, INC. | $26.27 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $25.09 | 2023-2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $23.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.67 | 2023 | Spravato |
| Philips North America LLC | $22.02 | 2024 | (5050) Extended Holter |
| Vertical Pharmaceuticals, LLC | $19.99 | 2025 | Relexxii |
| Novartis Pharmaceuticals Corporation | $19.51 | 2023 | |
| Kyowa Kirin, INC. | $19.46 | 2025 | |
| Lundbeck LLC | $19.31 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $16.32 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $15.11 | 2024 | Voquezna |
| Acella Pharmaceuticals, LLC | $14.52 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Respess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.